bioihbjkbjnl/mcl2 huggingface dataset:
Neural Components Underlying the Treatment of Adolescent Depression
Condition: Major Depressive Disorder
MeSH terms: Depression; Depressive Disorder; Depressive Disorder, Major
Study type: Interventional

Summary: 
      The goal of the study is to examine how cognitive behavioral therapy (CBT), a common
      treatment for adolescent depression, affects brain functioning. Depressed adolescents will
      complete an initial assessment consisting of an interview, questionnaires, computer tasks,
      and an EEG recording. EEG (electroencephalography) measures brain activity by recording the
      electrical activity along the scalp caused by the firing of neurons within the brain. They
      will then complete 12 sessions of cognitive behavioral therapy, which will be 50 minutes long
      and held once a week for 12 weeks. Before their third therapy session, participants will
      complete a computer task while EEG data are recorded. After completing the treatment, the
      participants will complete a final assessment, which will include questionnaires, computer
      tasks, and an EEG recording. They will also complete follow-up assessments over the phone 1,
      3, and 6 months after completing the treatment.

      This study will also include healthy control participants. They will complete an initial
      assessment consisting of an interview, questionnaires, computer tasks, and an EEG recording.
      Three weeks later, they will return to complete a behavioral task while EEG data are
      recorded. Twelve weeks after the initial assessment, they will complete a final assessment,
      which will include questionnaires, computer tasks, and an EEG recording.
    

Detailed description: 
      The purpose of the study is to examine the impact of individual cognitive behavioral therapy
      (CBT) for adolescent depression on neural functioning. Specifically, the study will utilize
      Brent and Poling's (1997) cognitive behavioral therapy (CBT) manual (Cognitive Therapy
      Treatment Manual for Depressed and Suicidal Youth), and investigators will examine pre- to
      post- neural activity patterns for children and adolescents who receive individual CBT for
      depression. Electroencephalography (EEG) techniques will be utilized to assess
      treatment-related effects on brain activity (i.e., anterior cingulate cortex and dorsolateral
      prefrontal cortex functioning). Neural activity patterns will also be compared to
      non-depressed, healthy controls.
    

Intervention name(s): Cognitive Behavioral Therapy
Intervention type(s): Behavioral
Intervention description(s): 12 sessions of cognitive behavioral therapy
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: MDD; depression; major depressive disorder; adolescent
Relationship Between Isometric Muscle Strength and Gross Motor Function in Children With Unilateral Cerebral Palsy
Condition: Hemiplegia; Cerebral Palsy
MeSH terms: Paralysis; Cerebral Palsy; Hemiplegia
Study type: Observational [Patient Registry]

Summary: 
      Muscle strength can be defined as the ability of skeletal muscle to develop force for the
      purpose of providing stability and mobility within the musculoskeletal system, so that
      functional movement can take place.
    

Detailed description: 
      Cerebral palsy describes a group of disorders of the development of movement and posture,
      causing activity limitation, that are attributed to non-progressive disturbances that
      occurred in the developing fatal or infant brain. The motor disorders of cerebral palsy are
      often accompanied by disturbances of sensation, cognition, communication, perception, and/or
      behaviour, and/or by a seizure disorder

      The development and changes in motor function, both natural and with therapy, can be assessed
      using the Gross Motor Function Measure (GMFM) created for children with CP
    

Intervention name(s): correlation
Intervention type(s): Other
Intervention description(s): A total of 97 children with CP between the ages of six and 12 years participated in the study. Muscle strength was measured with a handheld dynamometer. Motor function in children with CP was classified with the Gross Motor Function Classification System (GMFCS), graded with the Gross Motor Function Measure (GMFM)
Observational model: Case-Only
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        Muscle weakness was found in children with CP, increasing with severity of gross motor
        function, approximately 50% of the predicted muscle strength was needed to be able to walk
        without aids.
      
Keywords: Hemiplegia; Cerebral Palsy; muscle stength; gmfm
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Condition: Uveitis
MeSH terms: Uveitis; Panuveitis
Study type: Observational

Summary: 
      This study evaluates the long- term safety and effectiveness of adalimumab in participants
      with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.
    


Observational model: Cohort
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Participants with Non-infectious Intermediate-, Posterior-, or Pan-uveitis
      
Keywords: Humira; Adalimumab; Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females
Condition: Androgenetic Alopecia
MeSH terms: Alopecia; Alopecia Areata
Study type: Interventional

Summary: 
      The purpose of this study is to determine whether the Hair Loss Prevention Lotion named
      MEXIS, M.P.A.F., M6S PATENT is effective in the treatment of Androgenetic Alopecia.
    

Detailed description: 
      This study verifies whether the tested product has any efficacy in the treatment of
      Androgenetic Alopecia.

        -  The evaluated product (Hair Loss prevention Lotion) is called:MEXIS, MPAF, M6S PATENT.

        -  20 volunteers both men and women suffering from hair loss both in parties and over the
           entire scalp with age between 18 and 70 years have been selected for this test .

        -  Samples of the product have been applied following their usual use: as they are.

        -  On the selecting volunteers have been used:

             1. The pull test by pulling with fingers of some hair and counting them to estimate
                the evolution of the pathology.

             2. A sebum-meter to check the presence of scales on the scalp.

             3. A polarized light video-camera to check the redness of the scalp and to have a
                picture of hair and scalp.

        -  Volunteers were also asked about:

        -  Fluffiness

        -  Sheen

        -  Itching

        -  Presence of scales on scalp

        -  Oily hair

        -  Product's acceptability

        -  The readings are taken at 0 time (basal value), after 15 days (t15), 30 days (t30), 45
           days (t45), 45 days (t45), 60 days (t60) and 90 days (t90) by the experimenter in the
           medical studio. Then they analyzed and reported in a graph.

        -  Summarizing tables and graphs of the data were taken during experimentation.
    

Intervention name(s): Hair loss prevention lotion
Intervention type(s): Other
Intervention description(s): For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Baldness; Androgenetic Alopecia; Alopecia
Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity
Condition: Healthy Volunteers
Study type: Interventional
Phase: Phase 1

Summary: 
      To evaluate the changes in serum aldosterone and plasma renin activity on Day 0 and on Days 1
      and 10 after administration of 100 mg of eplerenone daily for 10 days.
    


Intervention name(s): Eplerenone or Placebo
Intervention type(s): Drug
Intervention description(s): Eplerenone 100 mg or Placebo, daily for 10 days.
Intervention MeSH terms: Eplerenone
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Other
Keywords: Eplerenone Aldosterone and Plasma Renin Activity responses Pharmacodynamics
Oral Nutritional Supplementation in Picky Eating Children
Condition: Children - Malnutrition
MeSH terms: Malnutrition
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      This study will investigate the effect of two oral nutritional supplements (ONS) along with
      dietary counseling vs dietary counseling alone on growth among picky eating children from
      India, aged > 24 months to ≤ 48 months over a period of 90 days.
    

Detailed description: 
      Study Objective:

      To investigate the effect of two oral nutritional supplements (ONS) along with dietary
      counseling vs dietary counseling alone on growth among picky eating children from India, aged
      > 24 months to ≤ 48 months over a period of 90 days.

      Number of Subjects / Length of Participation:

      Approximately 321 subjects (107 subjects per group) will be enrolled from estimated 8-10
      study centers to obtain at least 255 evaluable subjects (85 subjects per group), assuming 20%
      attrition rate. Expected total duration for the study is approximately 12 months.

      Study Design :

        -  Prospective, randomized, double blinded study, with two parallel treatment groups and an
           open-labeled control group multicenter clinical study Eligible subjects will be
           randomized into three groups

        -  Experimental Group 1: Oral nutritional supplement and dietary counseling. (List No
           S691/Z0)

        -  Experimental Group 2: Oral nutritional supplement and dietary counseling. (List No-
           P968/Z0)

        -  Control Group: Dietary counseling.
    

Intervention name(s): Oral nutritional supplement (List No S691/Z0); Oral nutritional supplement; Dietary Counselling
Intervention type(s): Dietary Supplement; Dietary Supplement; Other
Intervention description(s): (List No S691/Z0); (List No- P968/Z0); Regular dietary counseling conducted by a trained hospital dietitian.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Supportive Care
Thoracic Sympathetic Ganglion Block Inadvertent Spread
Condition: Thoracic; Sympathetic Ganglion, Injury
MeSH terms: Ganglion Cysts; Synovial Cyst
Study type: Observational

Summary: 
      This study wants to identify the incidence of inadvertend intercostal or epidural spread of
      thoracic sympathetic block
    

Detailed description: 
      Clinically, sympathetic blocks (SB) have been used widely to relieve the symptoms of SMP or
      to differentiate between SMP and sympathetically independent pain. In order to an SB has a
      diagnostic value, it requires the successful disturbance of the sympathetic activity for a
      proper duration of time.

      For the diagnosis of SMP using an SB, it is essential achieving complete interruption of the
      sympathetic activity while preserving the sensory and motor function. The sympathetic trunk
      at lumbar region runs on the anterolateral surface of the vertebral column from L1 to L4
      levels, and deep to the medial aspect of the psoas major muscle. Therefore, the investigators
      can hardly find epidural contrast spread during lumbar SB due to an anterior location of
      lumbar sympathetic ganglion to the lateral vertebral body. However, frequent psoas muscle
      injection can be encountered due to a close proximity of lumbar sympathetic ganglion.

      In contrast to lumbar sympathetic ganglion, the thoracic sympathetic ganglion is not
      separated from somatic nerves by muscles and connective tissue. Moreover, the upper thoracic
      ganglion runs on the posterior surface of vertebral column with close proximity to adjacent
      epidural region.

      This difference of thoracic sympathetic ganglion leads to a frequent epidural and intercostal
      spread if the investigators perform thoracic SB. Such spread to epidural and intercostal
      space lowers the diagnostic value of thoracic SB. In addition, serious adverse outcome can be
      encountered if neurolytic agent is injected into epidural or intercostal space for the
      purpose of thoracic sympathectomy. Considering the diagnostic value and safety of thoracic
      SB, evaluation of actual incidence of occurrence of intercostal and epidural spread is
      important.
    

Intervention name(s): thoracic sympathetic ganglion block
Intervention type(s): Other
Intervention description(s): thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
Observational model: Cohort
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        severe unilateral arm pain or edema which is intractable to conservative therapy
A Study of LY3457263 in Obese Participants
Condition: Overweight; Obesity
MeSH terms: Overweight
Study type: Interventional
Phase: Phase 1

Summary: 
      The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when
      administered in combination with tirzepatitide in overweight or obese participants. The study
      will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the
      body to remove it in overweight or obese participants. The study will last up to
      approximately 11 weeks.
    


Intervention name(s): LY3457263; Tirzepatide; Placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Administered SC.; Administered SC.; Administered SC.
Other intervention name(s): LY3298176
Intervention MeSH terms: Tirzepatide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Basic Science
A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      The main objective of this trial is to investigate the relative bioavailability of BI 425809
      given alone (Reference) compared to a combined administration with the moderate CYP3A4
      inducer bosentan (Test) following repeated oral administration.
    


Intervention name(s): BI 425809; bosentan
Intervention type(s): Drug; Drug
Intervention description(s): BI 425809; bosentan
Other intervention name(s): iclepertin; Tracleer®
Intervention MeSH terms: Bosentan; BI 425809
Allocation: Non-Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.
Condition: Basal Cell Carcinoma; Melanoma; Squamous Cell Carcinoma; Non-Malignant Skin Disorders
MeSH terms: Carcinoma; Carcinoma, Basal Cell; Skin Diseases
Study type: Observational

Summary: 
      The purpose of this study is to evaluate a new instrument that shines light and takes digital
      pictures of skin. The goal is to develop a technique that may enable fast and accurate
      detection of skin disorders and cancers for future clinical diagnosis and surgical use.
    


Intervention name(s): confocal microscopy in vivo
Intervention type(s): Procedure
Intervention description(s): A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Dermatology clinic
      
Keywords: 06-009; Confocal reflectance microscopy; shave-biopsy
Children's Familiarity With Snack Foods Changes Expectations About Fullness
Condition: Children
Study type: Observational

Summary: 
      The purpose of this study was to measure and quantify children's beliefs about the satiating
      properties (i.e. expected satiation)of snack foods. The investigators predicted that children
      who were especially familiar with snack foods would expect them to deliver greater satiation.
    

Detailed description: 
      Palatability is regarded as a major determinant of children's energy intake. However, few
      studies have considered other "non-hedonic" beliefs about foods. In adults there is emerging
      evidence that expectations about the satiating properties of foods are an important
      determinant of meal size, and that these beliefs are learned over time.

      In the current study, we measured and quantified children's 'expected satiation' across
      energy-dense snack foods using a psychophysical technique known as method of adjustment.
      Participants changed a comparison-food portion (pasta and tomato sauce) to match the
      satiation that they expected from a snack food. We predicted that children who were
      especially familiar with snack foods would expect them to generate greater satiation, and
      that children who were unfamiliar would match expected satiation based on the physical
      characteristics (perceived volume) of the foods.

      In our study, seventy 11- to 12-year-old children completed computerised measures of expected
      satiation, perceived volume, familiarity, and liking across six snack foods. Our analyses
      focused on the associations between these measures. This approach enabled us to establish
      differences in healthy behaviours that are evident across individuals.
    

Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        Community sample
      
Keywords: Obesity; Child; Dietary Habits
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Condition: Mild Cognitive Impairment (MCI); Alzheimer Disease
MeSH terms: Alzheimer Disease; Cognitive Dysfunction
Study type: Interventional
Phase: Phase 3

Summary: 
      The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque
      clearance in participants with early symptomatic Alzheimer's Disease (AD).
    


Intervention name(s): Donanemab; Aducanumab
Intervention type(s): Drug; Drug
Intervention description(s): Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.; Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
Other intervention name(s): LY3002813
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Alzheimer's Disease with MCI or Mild Dementia
Metabolomic Profiling of in Patients With type2 Diabetes
Condition: Diagnoses Disease; Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Observational

Summary: 
      To exam the metabolomic profiling of CSF and plasma in diabetes and establish the human CSF
      Metabolome Database of Type 2 DM.
    

Detailed description: 
      Human cerebral spinal fluid (CSF) is known to be a rich source of small molecule biomarkers
      for central neurological and neurodegenerative diseases. However, the metaboloic bases of CSF
      in diabetes patient have not been studied. In this plan, the investigators will use
      analytical platforms, including nuclear magnetic resonance (NMR), liquid chromatography-mass
      spectrometry (LC-MS), to perform quantitative metabolomics on human CSF and blood samples and
      further establish the human CSF Metabolome Database of DM. This work will can supply
      important CSF metabolic profit information and help to facilitate a wide range of metabolomic
      studies on central nervous system diseases and their associations disease.
    

Intervention name(s): spinal anesthesia
Intervention type(s): Procedure
Intervention description(s): Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
Intervention MeSH terms: Anesthetics
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients with received spinal anesthesia and had written informed consent
      
Biospecimen description: 
      Blood will be centrifuged for 10 min at 4 °C and 4000 rpm. The supernatant (plasma) samples
      will be stored in aliquots at -80 °C until analysis. CSF samples will be stored in aliquots
      at -80 °C before analysis. The sample will be analyzed using hydrogen-1 nuclear magnetic
      resonance (1H-NMR) and lipid chromatography-mass spectrometry (LC-MS) in the Metabolomic Core
      Laboratory at Chang Gung Memorial Hospital or Chang Gung University. Demographic data
      including age, gender, body weight, blood pressure and past medical data will be
      investigated. Blood HbA1c, blood/CSF glucose and insulin level also will be measured.
Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
Condition: Carcinosarcoma, Ovarian; Carcinosarcomas Uterine
MeSH terms: Carcinosarcoma; Mixed Tumor, Mullerian
Study type: Interventional
Phase: Phase 2

Summary: 
      Multicenter phase II study on trabectedin in patients advanced uterine and ovarian
      carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable
      toxicity. Disease response evaluation will be assessed every 9 weeks.
    

Detailed description: 
      This is a Phase II, multi-centre, single arm study aiming at evaluating efficacy and toxicity
      of Trabectedin in a population of advanced or recurrent ovarian and uterine carcinosarcoma.

      Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks
      via a central venous catheter.
    

Intervention name(s): Trabectedin
Intervention type(s): Drug
Intervention description(s): Chemotherapy drug
Other intervention name(s): Yondelis
Intervention MeSH terms: Trabectedin
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 3

Summary: 
      The aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment
      of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study.
    

Detailed description: 
      The aim of this study is to evaluate the therapeutic effect of escitalopram (cipralex) in the
      treatment of negative symptoms in schizophrenic patients receiving either typical or the
      newer atypical antipsychotics (olanzapine and risperidone) in a double-blind
      placebo-controlled study. As there is no drug treatment that is considered as first-line
      treatment in the treatment of negative symptoms, we thought that the comparison with placebo
      is plausible. However, it is important to note that the patients will receive the commonly
      used treatment for their disorder (i.e. antipsychotic medication).
    

Intervention name(s): escitalopram
Intervention type(s): Drug
Intervention MeSH terms: Escitalopram
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: negative symptoms; depression; ssri; schizophrenia